FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply

Lancet Oncol. 2014 Dec;15(13):e583-e584. doi: 10.1016/S1470-2045(14)71036-8. Epub 2014 Nov 24.

Authors

Volker Heinemann¹, Sebastian Stintzing²

Affiliations

¹ Comprehensive Cancer Center Munich, Munich 81675, Germany. Electronic address: [email protected].
² Department of Hematology and Oncology, University of Munich, Munich, Germany.

PMID: 25456375
DOI: 10.1016/S1470-2045(14)71036-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Camptothecin / analogs & derivatives*
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / pathology*
Female
Humans
Male

Substances

Antibodies, Monoclonal, Humanized
Camptothecin